TME Pharma: green light from the FDA to launch a ph.II trial

(CercleFinance.com) - TME Pharma has announced that the U.
S. Food and Drug Administration (FDA) has approved its IND application for NOX-A12 for evaluation in the treatment of glioblastoma, an aggressive adult brain cancer.

With the IND now approved by the FDA, TME Pharma plans to continue the clinical development of NOX-A12 in a randomized, controlled Phase 2 trial in around 100 patients with chemotherapy-resistant glioblastoma.

The study is due to be launched later this year, starting in Europe, once the necessary resources and preparations have been put in place.

' IND approval will also enable us to expand our clinical development in the United States, where we expect to generate significant interest from the medical community',commentedAram Mangasarian, CEO of TME Pharma.

Copyright (c) 2024 CercleFinance.com. All rights reserved.